499-81-0

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Pyridinedicarboxylic acid is used as a pharmaceutical intermediate for the development of various drugs. Its ability to inhibit butyrobetaine hydroxylase makes it a potential candidate in the treatment of conditions related to choline metabolism.
Used in Organic Synthesis:
3,5-Pyridinedicarboxylic acid serves as an important building block in the synthesis of complex organic molecules. Its unique structure allows for further functionalization and modification, making it a versatile compound in the field of organic chemistry.
Used in Enzyme Inhibition Studies:
As a competitive inhibitor of butyrobetaine hydroxylase, 3,5-Pyridinedicarboxylic acid is utilized in research to study the enzyme's function and its role in choline biosynthesis. This can lead to a better understanding of the enzyme's involvement in various biological processes and potential therapeutic applications.

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 4, p. 137, 1967 DOI: 10.1002/jhet.5570040127

InChI:InChI=1/C7H5NO4/c9-6(10)4-1-5(7(11)12)3-8-2-4/h1-3H,(H,9,10)(H,11,12)/p-2

Upstream product

• 591-22-0 3,5-Lutidine 
• 871890-30-1 3,5-diisopropenyl-pyridine 
• 59-67-6 nicotinic acid 
• 74-88-4 methyl iodide 
• 110-86-1 pyridine 
• 124-38-9 carbon dioxide 
• 4591-55-3 dimethyl pyridine-3,5-dicarboxylate 

Downstream Products

• 4591-56-4 diethyl 3,5-pyridinedicarboxylate 
• 4591-55-3 dimethyl pyridine-3,5-dicarboxylate 
• 15074-61-0 pyridine-3,5-dicarbonyl dichloride 
• 159236-37-0 N,N'-(pyridine-3,5-diyldicarbonyl)bis[(2S)-2-amino-3-phenylpropanoic acid] 
• 192518-51-7 C₂₉H₃₃N₅O₆ 
• 84254-39-7 3,5-di(N-β-phenethyl)carbamoylpyridine 
• 337904-92-4 5-[(tert-butoxycarbonyl)amino]nicotinic acid 
• 769935-82-2 pyridine-3,5-dicarboxylic acid bis-(3-{4-[tris-(4-tert-butyl-phenyl)-methyl]-phenoxy}-propyl) ester 
• 1023754-58-6 bis(pentafluorophenyl) pyridine-3,5-dicarboxylate 
• 98652-49-4 <8,18-bis(2-carbobenzyloxyethyl)-2,7,12,17-tetramethylporphyrin-3,13-pyridine-3,5-(1-oxo-2-aza)pentyl>cyclophane 
• 75340-05-5 19-benzyl-16,19-dihydro-2,13-diaza<4>paracyclo<4>(3,5)pyridinophane-1,14-dione 
• 75340-06-6 17-Benzyl-7,9,20-trimethyl-3,13,17-triaza-tricyclo[13.3.1.1^6,10]icosa-1⁽¹⁸⁾,6,8,10⁽²⁰⁾,15-pentaene-2,14-dione 
• 75340-04-4 17-Benzyl-7,9,20-trimethyl-2,14-dioxo-3,13-diaza-17-azonia-tricyclo[13.3.1.1^6,10]icosa-1⁽¹⁸⁾,6,8,10⁽²⁰⁾,15⁽¹⁹⁾,16-hexaene; bromide 
• 90433-47-9 C₂₈H₂₇N₃O₂ 

Relevant academic research and scientific papers

Synthesis and crystal structure of metal-organic frameworks [Ln2(pydc-3,5)3(H2O)9]n 3nH2O (Ln = Sm, Eu, Gd, Dy; pydc-3,5 = pyridine-3,5-dicarboxylate) along with the photoluminescent property of its europium one

Rare-earth metal-organic frameworks, [Ln2(pydc)3(H2O)9] n3nH2O (Ln = Sm, Eu, Gd, Dy; pydc = pyridine-3,5-dicarboxylate), were synthesized and characterized by elemental analysis, IR spectra and single-crystal X-ray diffraction. The solid-state photoluminescence measurements exhibited red light-emitting characteristic of europium (III) coordination polymer. The title compounds consist of one-dimensional dual chains, in which each metal atom is nine-coordinated with oxygen atoms.

Self-assembly of bis-β-diketone-based [M2 L 2] dinuclear platforms into 2-dimensional coordination polymers

A bis-β-diketone ligand incorporating a 3,5-substituted pyridine ring between its two β-diketone domains (1,1′-(pyridine-3,5-diyl)bis(4,4-dimethylpentane-1,3-dione), H2L1) and its interaction with three divalent cations (Cu2+, Zn2+ and Pd2+) is reported. Charge neutral dinuclear metallocycles of type [M2L12] were obtained in each case and their X-ray structures determined. [Pd2L12] incorporates two square-planar O4-coordinated metal centres. The zinc(ii) and copper(ii) complexes contain five-coordinate O4N1-metal centres in which the pyridyl nitrogen from adjacent [M2L12] metallocycles coordinates apically forming two-dimensional coordination polymers of type {[Zn2L12]n(dmf)n} and {[Cu2L12]n(dmf)n}. Desolvation of the coordination polymers led to loss of crystallinity.

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

On the formation of niacin (vitamin B3) and pyridine carboxylic acids in interstellar model ices

The formation of pyridine carboxylic acids in interstellar ice grains was simulated by electron exposures of binary pyridine (C5H5N)-carbon dioxide (CO2) ice mixtures at 10 K under contamination-free ultrahigh vacuum condi

Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib

This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.

Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib

This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a combination comprising an NSAID, or a pharmaceutically acceptable salt thereof, and an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-1 or cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. The invention combinations may also be further combined with other pharmaceutical agents depending on the disease being treated.

PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS

Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO 2, NR4R5, CN, or CF3, E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H. C1-C 6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH 2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3 to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted, n is an integer of from 0 to 6.

Substituted pyridine compounds

Disclosed herein are herbicidal pyridine compounds substituted at the 2- or 6-position with an OR2 moiety where R2 is hydrogen, lower alkyl, halomethyl, lower cyanoalkyl, alkenyl or alkynyl, as well as herbicidal compositions and herbicidal use of these compounds.

Penta-substituted pyridine compounds, herbicidal compositions and herbicidal method of use

Disclosed herein are herbicidal pyridine compounds substituted at the 3- and/or 5-position with a carboxylic acid-derived heterocyclic moiety, as well as herbicidal compositions and use of these compounds.

Primary 2H Kinetic Isotope Effects in the Base-catalysed 1,3-Prototropic Rearrangement of 1-Methylindene and 1,3-Dimethylindene

Rate constants and primary deuterium kinetic isotope effects (p. d. k. i. e. s.) have been determined for the base-catalysed rearrangement of 1-methylindene (1) and 1,3-dimethylindene (3) in the solvent o-dichloropbenzene at 30 deg C.The structurally similar tertiary amines 1-aza-adamantane, quinuclidine, 1,3-diaza-adamantane, DABCO, and 1,3,5-triaza-adamantane were used as catalysts.Substrate (3) gave a lower isotope effect than (1).The response in p. d. k. i. e.. due to a change in basicity of the amine catalyst is very similar for (1) and (3).Despite its intermediate basicity, DABCO showed a significantly lower p. d. k. i. e. for both substrates.The p. d. k. i. e. s. obtained for the other bases, with a pK at or around 2.6, were almost constant.The consequences of a possible influence of internal ion-pair return on the rearrangement of the substrates are discussed and related to the measured p. d. k. i. e. s.The similarity between the substrates and the symmetry in the rearrangement of (3) permits some rationalizations to be made.